馃搱 After progression on a third-generation EGFR TKI, izalontamab brengitecan (iza-bren) improved median PFS to 11.1 months vs 5.7 months with platinum-based chemotherapy in phase 3 PANKU-Lung01.
@myESMO #ESMO26 #lcsm #medtwitter #oncology
馃敆 Read more: https://www.onclive.com/view/iza-bren-improves-pfs-vs-platinum-chemo-in-egfr-mutated-nsclc-after-third-generation-tki
33 views 路 0 likes 路 0 reposts 路 0 replies
Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgPANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: OncLive.com 路 x.com